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Background: Themost often found complications in patientswith breast cancerwho received
radiotherapy are cardiac and pulmonary function disorders and development of second
malignancies.
Aim: To compare the intensity modulated radiotherapy with the 3D tangential beams tech-
nique in respect of dose distribution in target volume and critical organs they generate in
patients with early-stage breast cancer who received breast-conserving therapy.
Materials and methods: A dosimetric analysis was performed to assess the three radiotherapy
techniques used in each of 10 consecutive patients with early-stage breast cancer treated
with breast-conserving therapy. Radiotherapywas plannedwith the use of all the three tech-
niques: 3D tangential beams with electron boost, IMRT with electron boost, and intensity
modulated radiotherapy with simultaneous integrated boost.
Results: The use of the IMRT techniques enables more homogenous dose distribution in
target volume. The range of mean and median dose to the heart and lung was lower with
the IMRT techniques in comparison to the 3D tangential beams technique. The range of
mean dose to the heart amounted to 0.3–3.5Gy for the IMRT techniques and 0.4–4.3 for the
tangential beams technique. The median dose to the lung on the irradiated side amountedto 4.9–5Gy for the IMRT techniques and 5.6Gy for the 3D tangential beams technique.
ationConclusion: The applicbreast cancer allows to ob
permitting to reduce the d
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Table 1 – The range and median volumes of target,
contralateral breast and critical organs in 10 consecutive
patients with early-stage breast cancer treated with
breast-conserving therapy.
Anatomical structures Volume [cm3]
Range Median
Irradiated breast (CTV) 290.3–630.8 486.4
Tumour bed (boost target) 13.7–20.2 17.1
Contralateral breast 307.6–709.8 524.6
Heart 573.4–593.5 584.180 reports of practical oncology a
1. Background
Radiotherapy is an integral component of breast-conserving
therapy in patients with early-stage breast cancer. In these
cases, radiotherapyhas the effect of reducing locoregional fail-
ures in 70% of patients and increasing disease-free survival
rates (in 85–90%).1,2
This favourable inﬂuence on treatment results leads to
improved survival. Therefore, the aim of therapy should also
be to minimise the risk of complications which may develop
in critical organs. In patients with early-stage breast cancer,
the critical organs in radiotherapy are: lungs, heart, left ante-
rior descending coronary artery (LAD) and contralateral breast.
The most often found complications in these patients are car-
diac and pulmonary function disorders and development of
second malignancies.3–6
Cardiac complicationsmay develop after 10 years following
radiotherapy and they aremost frequently observed inwomen
with left-sided breast cancer.2,7–12 These complications cause
a 30% increase in cardiovascular deaths after the period of 10
years following radiotherapy.7
Other complications related to radiotherapy are those
affecting the lungs. Pulmonary complications are conﬁned to
antero-lateral peripheral (subpleural) region of the lung on the
irradiated side. They are usually divided into early and late
complications. Immediately after radiotherapy, patients may
develop radiation pneumonitis which later evolves into lung
ﬁbrosis.3
The lower risk of complications connected with radiother-
apy correlates with reduction of dose and irradiated volume
in critical organs.11–13 This effect has been observed for radio-
therapy techniques using 3D CT-based dosimetry methods
(conformal radiotherapy, intensity modulated radiotherapy
(IMRT), moderate deep inspiration breath hold (mDIBH)).4,14–16
At the same time, improvements in radiotherapy planning
afford possibilities for obtaining more homogenous dose dis-
tribution in target volume.
Patientswith early-stage breast cancer are at increased risk
of second primarymalignancies.3,12 Themost often diagnosed
are lung cancer, ovarian cancer, sarcomas and contralateral
breast cancer.17–20 The development of second malignancies
depends not only on radiotherapy but also on other car-
cinogenous factors.
2. Aim
The purpose of this paper is to compare the intensity mod-
ulated radiotherapy (IMRT) with the 3D tangential beams
technique in respect of dose distribution in target volume
and critical organs they generate in patients with early-stage
breast cancer who received breast-conserving therapy.
3. Materials and methodsA dosimetric analysis was performed at the Oncology Centre
in Cracow to assess the three radiotherapy techniques used in
patients with left-sided early-stage breast cancer treated with
breast-conserving therapy:LAD 0.9–1.7 1.2
Lung on irradiated side 1131.0–1270.8 1206.4
Contralateral lung 1272.5–1677.2 1423.1
1. 3D tangential beams (covering the breast) with electron
boost to the tumour bed;
2. intensity modulated radiotherapy (IMRT) irradiation to
breast with electron boost to the tumour bed;
3. intensity modulated radiotherapy with simultaneous inte-
grated boost (IMRT-SIB).
In each of 10 consecutive patients after breast-conserving
therapy the postoperative radiotherapy was planned with the
use of all three of the above techniques. All plans performed
for linear accelerator Clicac 2300 C/D (applying of 6MV pho-
ton beam and 12 or 16MeV electron beams) were prepared
employing the Eclipse treatment planning system with Helio
module.
Fig. 1 presents the arrangement of radiotherapy beams in
the three techniques being compared.
The target volume (CTV) covered the breast with regard
to the tumour bed. The margin of 1 cm was added to CTV to
create PTV.
The critical organs for this analysis were: the heart, LAD,
the lung on the irradiated side and the contralateral breast.
Table 1 presents the range and median volume of target,
the contralateral breast and the other critical organs.
In all cases, the total dose was 42.5Gy given to the whole
breast with boost of 10Gy given to the tumour bed. The frac-
tion dose amounted to 2.5Gy.
The energy and gantry of electron beams for boost were
individually established depending on a patient’s anatomy
and localisation of the tumour bed in the breast.
The optimal radiotherapy plans were prepared on the basis
of CT scans.
The dose values (range of mean and median) and dose dis-
tribution in target volume and critical organs were compared
for the three radiotherapy techniques.
4. Results
Table 2 presents details of dosage and Fig. 2 shows the dose
distribution in target volume for eachof the three radiotherapy
technique.
The use of the IMRT techniques enables more homogenous
dose distribution in target volume. Furthermore, the use of
IMRT-SIB leads to shortening of the treatment time.
The information on doses in target volume and in critical
organs in each of the three radiotherapy techniques used are
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Table 2 – The range of mean and median doses to target volum
early-stage breast cancer treated with breast-conserving therap
Target volume Radiothe
3D+electron boost
Breast (CTV) 40.4–54.6
46.3
Tumour bed 51.8–54.5
53.7ues used in postoperative treatment of patients with
.
techniques than with the classical 3D tangential beams tech-
nique. Especially marked was the difference observed in the
value of V20 for the lung on the irradiated side. This median
value amounted to 10.7% in the 3D tangential beams tech-
nique and 6% in the IMRT techniques. The medium value
of V20 evaluated for both lungs amounted to 5% in the 3D
e in three techniques in 10 consecutive patients with
y.
rapy techniques dose [Gy] (range/median)
IMRT+electron boost IMRT-SIB
41.0–54.9 41.2–53.3
45.8 45.3
52.6–54.9 49.1–53.3
53.7 52.2
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Table 3 – The range of mean and median doses to contralateral breast and critical organs in three techniques in 10
consecutive patients with early-stage breast cancer treated with breast-conserving therapy.
Critical organs Radiotherapy techniques dose [Gy] (range/median)
3D+electron boost IMRT+electron boost IMRT-SIB
Contralateral breast 0.1–1.8 0.0–1.4 0.0–1.5
0.4 0.3 0.2
Heart 0.4–43.1 0.3–35.9 0.3–35.0
1.7 1.6 1.6
LAD 0.7–7.4 0.6–8.0 0.7–7.6
2.7 3.0 2.8
Lung on irradiated side 0.3–50.1 0.1–49.4 0.1–44.5
5.6 5.0 4.9V 20 value (for lung on irradiated side) 9–14%
10.7%
V 20 value (for both lungs) 4–6%
5%
tangential beams technique and 2–2.3% in the IMRT tech-
niques.
Similar observation refers to doses received by the con-
tralateral breast. For IMRT, the dose in this volume amounted
to 0.2–0.3Gy and was lower than that of the classical 3D tan-
gential beams technique.
Table 4 presents the range ofmean andmedian dose to 50%
of volume of the contralateral breast and critical organs.
These data show that the dose in 50% of volume of critical
organs was lower in the IMRT techniques than in the classical
3D tangential beams technique. Especially marked were the
differences concerning the heart and the lung on irradiation
side.
5. Discussion
The role of postoperative radiotherapy in the treatment of
patients with early-stage breast cancer has been identi-
ﬁed and conﬁrmed in some clinical studies.1 The results of
metaanalysis performed by Early Breast Cancer Trialists’ Col-
laborative Group (EBCTCG) showed that adjuvant radiotherapy
has improved treatment effects in patients with breast can-
cer. This improvement is expressed by signiﬁcant decrease in
locoregional relapse and increase in overall survival rates.2,5
The therapeutic gain for postoperative radiotherapy amounts
to 70% reduction of locoregional failures and 5.3% increase of
survival.5
Patients with early-stage breast cancer receive radiother-
apy after a breast-conserving surgery. The total dose given to
the whole breast amounts to 50Gy, and it is classically frac-
tionated (average fraction dose 1.8–2.0Gy, is given once-a-day,
ﬁve days in aweek). Furthermore, the boost is given to increase
dose to the tumour bed. Data from clinical studies conﬁrmed
thenecessity to apply boost in these patients. Clinical observa-
tions showed that majority of patients developed local relapse
in the tumour bed.1,21 The results of EORTC study conﬁrmed
that the employment of boost had the effect of decreasing
local relapse ratio from 7.3% to 4.3%.22The average boost dose is 10–20Gy and depends on diam-
eter of the primary tumour and microscopic completeness of
surgical therapy. Theboostmaybegivenusing electronbeams,
brachytherapy or photon beams.14–8% 5–7%
6% 5.7%
2–3% 1–3%
2.3% 2%
Randomised EORTC study was performed to evaluate
the impact of boost dose on reduction of local control. It
was observed that local recurrences appeared in 10.8% of
patients who received 26Gy, whereas after the dose of 10Gy,
the incidence of failures was higher and averaged 17.5%.
These differences were not statistically signiﬁcant. How-
ever, in patients who received high boost dose, signiﬁcantly
more frequent occurrence of ﬁbrosis in subcutaneous tissues
was noted. This complication led to unfavourable cosmetic
consequence.23
As already mentioned, in patients with early-stage breast
cancer, radiotherapy with classical fractionation is usually
employed both for breast irradiation and boost to the tumour
bed.
In our study, patients received radiotherapy in a shortened
overall treatment time (the fraction dose average of 2.5Gy)
under the study conducted on Polish population since 2003. In
this study the whole breast dose amounts to 42.5Gy, given in
17 fractions, and the boost dose to the tumour bed is increased
by 10Gy in 4 fractions. The results obtained up to date show
the similar efﬁciency as in the case of 50Gy given in 2-Gy
fractions.24
Radiotherapy improves treatment outcome in patients
with breast cancer, but is connected with a risk of compli-
cations. The most serious late side effects include cardiac and
pulmonary complications and second malignancies localized
in the lung or the contralateral breast.3,5
The cardiac complications occur over 10 years after treat-
ment and are responsible for 30% increase in cardiovascular
deaths in the period of more than 10 years after radio-
therapy. These data apply to both breast-conserving therapy
and post-mastectomy irradiation.7,10,12 These complications
develop more frequently in women treated for left-sided
breast cancer.2,8–11 In these patients the cardiacmortality ratio
was 1.2 for up to 10 years, increased to 1.42 for the 10–14
years, and averaged 1.58 for over 15 years after radiotherapy.12
Radiation can damage the myocardium and endothelium
of LAD, thus becoming responsible for development of car-
diac dysfunctions. Injury to endothelium of coronary arteries
leads to microcirculary disturbances and in consequence to
changes in the myocardial perfusion.11,13,25–28 Radiotherapy
dependent perfusion defects occurred 6 months after treat-
ment and were observed in approximately 40% of patients
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Table 4 – The range of mean and median doses to 50% of volume of contralateral breast and critical organs in three
techniques in 10 consecutive patients with early-stage breast cancer treated with breast-conserving therapy.
Critical organs Radiotherapy techniques dose [Gy] (range/median)
3D+electron boost IMRT+electron boost IMRT-SIB
Contralateral breast 0.3–0.4 0.2–0.3 0.2–0.3
0.3 0.2 0.2
Heart 1.0–1.8 0.9–1.0 0.9–1.2
1.3 0.9 0.9
LAD 2.6–3.1
2.9
Lung on irradiated side 1.5–2.0
1.7
Fig. 2 – The comparison of dose distribution in target
volume in three techniques used in postoperative
treatment of patients with early-stage breast cancer treated
with breast-conserving therapy.1.9–3.0 1.6–3.1
2.3 2.4
0.9–1.7 1.2–2.0
1.3 1.5
within 2 years after treatment.28,29 The development of car-
diac complications is related to the following factors: total
dose, fractionation scheme, irradiated volume, patient age,
earlier usage of cardiotoxic chemotherapy, as well as coex-
istence of diabetes and smoking habit, which promote the
development of circulatory disturbances.11,28
The literature shows that the method of conducting
radiotherapy (technique applied, arrangement of beans) can
indirectly affect the development of cardiac complications.
The most important factors are dose distribution, maximal
dose in critical organs and dose per fraction.11–13,15,16
Pulmonary complications are the second important group
of complications which may develop in patients treated for
breast cancer. Immediately after radiotherapy, patients may
develop radiation pneumonitis which later evolves into lung
ﬁbrosis in the irradiated volume. The clinical consequence of
this complication is respiratory insufﬁciency. The estimation
of lung volume which received a dose equal or higher than
20Gy (valueV20) is an important factor forminimizing the risk
of complication. In patients with early-stage breast cancer the
above changes are localized in the antero-lateral subpleural
part of the lung on the irradiated side.3,4 The lowering of lung
dose is possible with the use of improved radiotherapy tech-
niques such as: tangential beams, conformal radiotherapy,
moderate deep inspiration breath hold or intensity modulated
radiotherapy.4,15,16,30
IMRT techniques afford possibilities for obtaining more
homogenous dose distribution in target volume (breast and
tumour bed) and at the same time reducing the dose in criti-
cal organs. In IMRT, the volume which receives lower dose is
greater than in the other radiotherapy techniques.31–34 Reduc-
tion of acute reaction intensity is observed which, in turn,
largely affects patients quality of life.33,35,36
Data published and own results conﬁrm that IMRT allows
to decrease dose to critical organs, especially to the lungs.37–39
We have observed that maximal and medium dose in the
heart and the lung and V20 in the lung on the irradiated side
and V20 evaluated for both lungs were lower for IMRT than for
3D tangential beams. Unfortunately, this effect was not found
in relation to the dose received by LAD.
Apart from the inﬂuence on dose distribution in target vol-
ume and critical organs, IMRT also offers the reduction of dose
40,41to the contralateral breast.
As suggested by published data, when IMRT was used we
observed a decrease of maximal and medium doses to the
contralateral breast.
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Fig. 3 – The comparison of dose-volume histograms (DVH) in target volume and critical organs in three techniques used in
ancepostoperative treatment of patients with early-stage breast c
beams+electron boost, IMRT+electron boost, IMRT-SIB).
Some authors suggest that using the IMRT techniques
can increase the risk of second malignancies. This partic-
ularly concerns patients with early-stage breast cancer and
refers to the risk of contralateral breast and lung cancers.6 It
should be pointed out that using IMRT involves more treat-
ment ﬁelds and, in consequence, larger volume of critical
organs is exposed to lower doses. Moreover, in the IMRT tech-
nique the number of monitor units is increased which can
have an impact on incidence of cancers localized in critical
organs.17,22,42r treated with breast-conserving therapy (3D tangential
It is believed that in patients with early-stage breast
cancer, development of second malignancies depends on:
age, genetic factors, exposition to radiotherapy as well as
other carcinogens.18–20 In patients treated for early-stage
breast cancer, the increased risk of second malignan-
cies begins 5 years after therapy. The incidence after
10 years is 16%.18,19 The risk of lung cancer is 2 at
10 years and increases to 2.7 at over 15 years after
radiotherapy.12
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. Conclusion
he application of the IMRT techniques in radiotherapy
atients with early-stage breast cancer treated with breast-
onserving therapy affords possibilities to obtain more
omogenous dose distribution in target volume.
IMRT techniques have permitted to reduce the dose to crit-
cal organs, i.e. the heart, the lung (on irradiated side) and the
ontralateral breast.
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